Actelion Pharmaceuticals Ltd. v. Kappos

972 F. Supp. 2d 51, 2013 WL 5310176, 2013 U.S. Dist. LEXIS 135854
CourtDistrict Court, District of Columbia
DecidedSeptember 23, 2013
DocketCivil Action No. 2010-1145
StatusPublished
Cited by5 cases

This text of 972 F. Supp. 2d 51 (Actelion Pharmaceuticals Ltd. v. Kappos) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Actelion Pharmaceuticals Ltd. v. Kappos, 972 F. Supp. 2d 51, 2013 WL 5310176, 2013 U.S. Dist. LEXIS 135854 (D.D.C. 2013).

Opinion

MEMORANDUM OPINION

RICHARD J. LEON, District Judge.

Plaintiff Actelion Pharmaceuticals Ltd. (“Actelion” or “plaintiff’) brought this suit against defendant David J. Kappos in his official capacity as Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office (“USPTO”). Plaintiff claims that USPTO improperly determined the amount of patent term adjustment to which it is entitled. Before the Court are plaintiffs Motion for Summary Judgment and defendant’s Cross-Motion for Summary Judgment. Upon consideration of the pleadings, record, and relevant law, plaintiffs motion is DENIED and defendant’s motion is GRANTED.

BACKGROUND

Patents are issued by USPTO for a term ending 20 years from the date the patent application was filed, as opposed to the date the patent is issued. 35 U.S.C. § 154(a)(2). As a result, delays by USP-TO in examining a patent application can reduce the effective term of that patent. See Wyeth v. Kappos, 591 F.3d 1364, 1366 (Fed.Cir.2010). To address this issue, Congress provided that a patent term will be extended to account for certain delays. See id.; 35 U.S.C. § 154(b).

The procedures for determining such a “patent term adjustment” (“PTA”) are governed by § 154(b)(3). Several types of delay can figure into calculating the overall PTA, two of which are relevant for plaintiff in this case. First, so-called “A Delay” days accrue if USPTO fails to take certain specified actions within certain time periods, such as failing to respond to a patent application within 14 months of its filing. See § 154(b)(1)(A). Second, “B Delay” days accrue if USPTO fails to issue a patent within three years of the filing of the application. See § 154(b)(1)(B). After determining the proper amounts of A and B Delay, USPTO determines the extent of any overlap between the two types of delay to arrive at the overall PTA. See § 154(b)(2)(A).

USPTO makes an initial PTA determination prior to patent issue and includes it with the written “notice of allowance” informing an applicant that he is entitled to a patent. See 35 U.S.C. § 154(b)(3)(B)(i); 37 C.F.R. § 1.705(a) (2006). The applicant must pay an issue fee within three months; once payment occurs, USPTO issues the patent and determines the final PTA as of the date of the patent grant, noting this determination on the face of the patent. See 35 U.S.C. § 151; 37 C.F.R. § 1.705(d) (2006). If the applicant disagrees with the PTA, the statute entitles him to “one op *53 portunity to request reconsideration of any [PTA] determination made by the Director.” 35 U.S.C. § 154(b)(3)(B)(ii).

Further, the statute permits the applicant to appeal USPTO’s PTA determination to a federal district court. Specifically, the statutory provision, entitled “Appeal of patent term adjustment determination,” provides:

An applicant dissatisfied with a determination made by the Director under paragraph (3) [Procedures for patent term adjustment determination] shall have remedy by a civil action against the Director filed in the United States District Court for the District of Columbia within 180 days after the grant of the patent. Chapter 7 of title 5 [5 U.S.C. §§ 701-706] shall apply to such action

§ 154(b)(4)(A) (2010). 1

On January 7, 2010, in Wyeth v. Kappos, 591 F.3d 1364 (Fed.Cir.2010), the Federal Circuit rejected USPTO’s method for determining A and B Delay overlap, finding that USPTO had relied on an erroneous interpretation of 35 U.S.C. § 154(b). 2 Following the Wyeth decision, USPTO changed its method for making future PTA determinations to align with the court’s holding. In addition, USPTO created an “Interim Procedure,” effective February 1, 2010, that permitted patentees to request a PTA recalculation from USPTO so long as their patent was issued prior to March 2, 2010 and their request for recalculation was filed within 180 days of the patent grant. See Interim Procedure, 75 Fed. Reg. 5043, 5043 (Feb. 1, 2010). Thus, in effect, only patents granted within the 180 days prior to February 1, 2010, were eligible for a PTA recalculation using the new post-Wyeth interpretation of A and B Delay overlap.

The material facts are not in dispute in the instant case. Plaintiff, a pharmaceutical company, holds U.S. Patent No. 7,094,-781 (the “'781 Patent”). Compl. [Dkt. # 1] ¶¶ 3, 9. The application for the '781 Patent was filed on May 27, 2003. Id. ¶ 8. USPTO issued the '781 patent on August 22, 2006, with a PTA of 312 days using its pre-Wyeth method of calculating A and B Delay overlap. Id. ¶ 11; Pl.’s Mot. Summ. J. and Mem. Supp. [Dkt. # 9] (“PL’s Mot.”) at 4. Plaintiff never filed a request for reconsideration of its PTA with USPTO. Def.’s Cross-Mot. Summ. J. and Mem. Supp. [Dkt. # 10] (“Def.’s Mot.”) at 2. And Plaintiff filed this civil action on July 6, 2010 — more than 180 days after the August 22, 2006 patent grant. See Compl.

STANDARD OF REVIEW

Summary judgment is appropriate when the record shows that there is no genuine dispute as to any material fact and the moving party is entitled to judgment as a *54 matter of law. FecLR.Civ.P. 56; Celotex Corp. v. Catrett, 477 U.S. 317, 322, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). The court will accept as true the evidence of the non-moving party, and draw “all justifiable inferences” in his favor. Anderson v. Liberty Lobby, Inc. 477 U.S. 242, 255, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986) (citation omitted). A genuine dispute about a material fact only exists if “the evidence is such that a reasonable jury could return a verdict for the nonmoving party.” Id. at 248, 106 S.Ct. 2505.

ANALYSIS

Plaintiff moves for summary judgment, seeking a recalculation of its PTA based on the

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Nippon Shinyaku Co. v. Iancu
369 F. Supp. 3d 226 (D.C. Circuit, 2019)
Nippon Shinyaku Co., Ltd. v. Kappos
District of Columbia, 2019
Merck Sharp & Dohme Corp. v. Kappos
75 F. Supp. 3d 16 (District of Columbia, 2014)
United States Ex Rel. McBride v. Halliburton Co.
44 F. Supp. 3d 69 (District of Columbia, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
972 F. Supp. 2d 51, 2013 WL 5310176, 2013 U.S. Dist. LEXIS 135854, Counsel Stack Legal Research, https://law.counselstack.com/opinion/actelion-pharmaceuticals-ltd-v-kappos-dcd-2013.